An observational study in COVID-19, Coronavirus Disease 2019 and Influenza, sponsored by Pfizer. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Pfizer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.
Among the 69 studies in COVID-19 by Pfizer, this one is the 16th largest by planned enrollment of the 28 observational ones that give a count, is one of 18 that started in 2022, is one of 28 observational ones, and was the 20th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
Pfizer · Sites in Korea, Republic of
Ages 19+
Pfizer · Sites in United States, Bulgaria, Japan and 4 more countries
Ages 0–17
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 11 · Phase 3 8 · Phase 4 1
First in 2020; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 999 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 20 across the 41 interventional studies, 2,038 across the 28 observational. Of the 53 that completed or were terminated, 39 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
5 of the studies in COVID-19 by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06613984PfizerKorean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | 2026-12-30 |
| NCT05032976PfizerKorea Comirnaty Post-marketing Surveillance | 2027-01-24 |
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in COVID-19 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to understand:
This study will enroll participants who are:
The study will collect vaccine history information from participants who are ready to take part in the study. Participant will be emailed a form with questions about their health related to COVID-19 or influenza during multiple follow-ups over a 6-month period.
This is a prospective non-interventional longitudinal cohort survey study. Repeated measures on PROs including: symptoms (prevalence, frequency, duration, and severity), EQ-5D-5L, and WPAI over 6 months will be collected and evaluated.
COVID-19 Cohort: Participants 18 years or older with test-confirmed COVID-19 illness and at least one patient-reported symptom.
Influenza Cohort: Participants 18 years or older with test-confirmed influenza illness and at least one patient-reported symptom.
All study objectives and outcomes will be assessed separately for the two study cohorts. Influenza cohort is only included in updated study analyses.
Participants are 18 years or older who are self-reported symptomatic, who tested positive with RT-PCR at any of the approximately 5,000 CVSH COVID-test sites and consented to participate in the PRO study.
Updated study analysis included participants 18 years or older who are self-reported symptomatic, with test-confirmed illness when tested at any of CVS pharmacy COVID-19 or influenza test sites, and consent to participate in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- No symptoms reported in the study screening questionnaire
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test-confirmed COVID-19 illness and at least one patient-reported symptom
Biological: COVID-19 Vaccine
Test-confirmed influenza illness and at least one patient-reported symptom
Receipt of Pfizer BioNTech COVID-19 vaccine
Change in Health Related Quality of Life (HRQoL) using EQ-5D-5L
To assess the change in HRQoL using EQ-5D-5L before COVID-19 or influenza and over a 6-month period following the test-confirmed COVID-19 or influenza.
Time frame: 6 months
EQ-5D-5L Utility Index (UI) scores
To estimate the EQ-5D-5L UI scores and their change across six time points in a span of six months following the test-confirmed COVID-19 or influenza.
Time frame: 6 months
Visual Analog Scale (VAS) scores
To estimate the VAS scores and their change across six time points in a span of six months following the test-confirmed COVID-19 or influenza.
Time frame: 6 months
WPAI scores
To estimate the WPAI scores and their change across six time points in a span of six months following the test-confirmed COVID-19 or influenza.
Time frame: 6 months
Prevalence and duration of SARS-CoV-2 symptoms
To characterize prevalence and duration of SARS-CoV-2 symptoms before COVID-19 and up to 6 months (acute phase and Long COVID).
Time frame: 6 months
Prevalence, Severity, and duration of influenza symptoms aggregated as index score area under the curve
To characterize prevalence and duration of influenza symptoms before influenza and up to 6 months (acute phase and Long Flu). Outcome will be aggregated by assigning a point-scale to the symptom severity and calculating the area under the curve of the severity index score.
Time frame: 6 Months
Fatigue before COVID-19
To assess fatigue (using PROMIS questionnaire Fatigue short-form 8a) before COVID-19 and over a six-month follow-up.
Time frame: 6 months
Fatigue after COVID-19
To estimate the PROMIS questionnaire Fatigue short-form 8a score and its change across six time points in a span of six months following the RT-PCR confirmed COVID-19.
Time frame: 6 months
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Started Jan 2022 (actual). Primary completion is estimated for Jan 2027, 60 months after the start.
Of 134 industry-sponsored observational studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's planned 60 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.